Cincinnati Children's is conducting a research study to evaluate the use of a medication, methylphenidate (QuillivantXR), with children and teens with Down syndrome and ADHD.
Children and teens 6 to 17 years old with Down syndrome and diagnosed or suspected ADHD may be eligible to participate.
This study includes 13 study visits (5 of the 13 are telehealth). 2 of these visits are screening visits. The visits include some or all of these components:
You will be given a consent form that thoroughly explains all the details of the study. A member of the study staff will review the consent form with you and will be sure that all your questions are answered.
Families will receive a comprehensive assessment, including intelligence, behavioral and cognitive assessments at no charge. Families will also receive 4 months of a therapeutic dose of methylphenidate (QuillivantXR) at no charge. The participant will receive cardiac and medical oversight for the duration of the study. Overall, the information learned from this study may help children with Down syndrome and ADHD and it may also help doctors with their diagnostic and treatment efforts in the future.
Possible risks and discomforts will be discussed with parents or guardians interested in learning more about the study.
Families will receive up to $225.
Emily Hoffman
513-803-3641
emily.hoffman1@cchmc.org
Cincinnati Children’s Hospital Medical Center
3333 Burnet Ave.
Cincinnati, OH 45229-3039
Anna Esbensen, PhD
Developmental and Behavioral Pediatrics - Psychology
Cincinnati Children’s Hospital Medical Center
Tanya Froehlich, MD
Developmental & Behavioral Pediatrics
Cincinnati Children’s Hospital Medical Center